NEWS

May 15, 2025

Announcement of Joint Research Collaboration with the University of Tokyo and Nara Medical University.
We are pleased to announce that our company has entered into a joint research agreement with the University of Tokyo Graduate School and Nara Medical University for the development of a therapeutic drug for rare blood diseases using bispecific DNA aptamers. By combining each institution’s technologies and expertise, we aim to develop innovative nucleic acid therapeutics. 

March 31, 2025

Strategic Partnership Agreement Signed with Kanematsu Chemicals Corporation.

We are pleased to announce that we have entered into a basic strategic partnership agreement with Kanematsu Chemicals Corporation, a specialized trading company in the chemical and life sciences fields.
Through this partnership, we aim to combine our proprietary contract research services for nucleic acid DNA aptamer discovery with Kanematsu Chemicals’ extensive international network. This collaboration will enable us to better meet global customer needs and jointly accelerate the development of pharmaceuticals and diagnostic agents for clients overseas.

Feb 18, 2025

Joint Research Agreement with Professor Hoshino’s Laboratory at Kyushu University

We are excited to announce that LinkBIO Inc. has entered into a joint research agreement with the laboratory of Professor Tomo Hoshino at the Faculty of Engineering, Kyushu University.
By combining our respective technologies and expertise, we will take on the challenge of pioneering an entirely new approach to drug discovery using precision polymers, read more:
https://prtimes.jp/main/html/rd/p/000000006.000066383.html
Kyushu University press release
https://www.kyushu-u.ac.jp/ja/notices/view/2827

December 2, 2024

Our Aptamer Discovery Service Featured in Funakoshi News

Our “Aptamer Discovery Service using the MACE®-SELEX Method” was featured in the December 1, 2024 issue (No. 802) of Funakoshi News (Drug Discovery Support, p.25), read more here:
https://fnkprddata.blob.core.windows.net/domestic/news/241201pdf/241201.pdf

September 11, 2024

Article by Our CEO and CTO Published in Journal of Experimental Medicine (JEM) Special Issue

An article co-authored by our CEO, Yuki Inami, and CTO, Associate Professor Keitaro Yoshimoto of the University of Tokyo, titled “Rebooting Cyborg RNA Aptamer Drug Discovery with Natural DNA Aptamers,” has been published in the special issue of Experimental Medicine (Vol. 42 No. 15) by Yodosha, titled “From Information to Material: Advances in Non-Coding RNA Research, read more here:
https://www.yodosha.co.jp/jikkenigaku/book/9784758104210/index.html

July 9, 2024

Patent Granted in South Korea for Aptamer Screening Method

We are pleased to announce that the patent titled “Method for Screening Nucleic Acid Aptamers” (Applicants: The University of Tokyo and LinkBio Inc.) has been granted in South Korea.
Patent Number: 10-2672039

JJune 17, 2024

Our project has been selected by the Japan Agency for Medical Research and Development (AMED). (Lead Institution: The University of Tokyo; Collaborators: Nara Medical University, LinkBio), read details here:
https://prtimes.jp/main/html/rd/p/000000005.000066383.html

May 31, 2024

Our CTO, Associate Professor Keitaro Yoshimoto of the University of Tokyo, was featured in an interview article in Drug Discovery News.

He discusses groundbreaking advances in synthetic DNA for safer thrombosis treatment, read details here
https://www.drugdiscoverynews.com/synthetic-dna-provides-a-safer-blood-clot-treatment-15938